Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Lakefront Biotherapeutics total assets
Total assets on the balance sheet at the end of each period.
Lakefront Biotherapeutics's total assets was €3.41B at Dec 31, 2025. For fiscal 2025 it was €3.41B, down 17.6% from the year before. Over ten years it grew 22.6% a year on average. The highest annual figure on record is €6.07B in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €3.41B | -17.6% |
| FY2024 | Dec 31, 2024 | €4.14B | -5.1% |
| FY2023 | Dec 31, 2023 | €4.36B | -8.0% |
| FY2022 | Dec 31, 2022 | €4.73B | -8.8% |
| FY2021 | Dec 31, 2021 | €5.19B | -9.2% |
| FY2020 | Dec 31, 2020 | €5.72B | -5.8% |
| FY2019 | Dec 31, 2019 | €6.07B | +321.6% |
| FY2018 | Dec 31, 2018 | €1.44B | +11.9% |
| FY2017 | Dec 31, 2017 | €1.29B | +18.7% |
| FY2016 | Dec 31, 2016 | €1.08B | +144.8% |
| FY2015 | Dec 31, 2015 | €442.51M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | €3.41B | -34.4% |
| Q4 FY2024 | Dec 31, 2024 | €4.14B | -23.8% |
| Q4 FY2023 | Dec 31, 2023 | €4.36B | -23.8% |
| Q4 FY2022 | Dec 31, 2022 | €4.73B | -19.1% |
| Q4 FY2021 | Dec 31, 2021 | €5.19B | -14.4% |
| Q2 FY2021 | Jun 30, 2021 | €5.43B | +299.9% |
| Q4 FY2020 | Dec 31, 2020 | €5.72B | +297.2% |
| Q2 FY2020 | Jun 30, 2020 | €5.85B | +385.9% |
| Q4 FY2019 | Dec 31, 2019 | €6.07B | +371.8% |
| Q2 FY2019 | Jun 30, 2019 | €1.36B | +25.3% |
| Q4 FY2018 | Dec 31, 2018 | €1.44B | +225.3% |
| Q2 FY2018 | Jun 30, 2018 | €1.20B | – |
| Q4 FY2017 | Dec 31, 2017 | €1.29B | – |
| Q4 FY2016 | Dec 31, 2016 | €1.08B | – |
| Q4 FY2015 | Dec 31, 2015 | €442.51M | – |
See a number that looks wrong?